Containing pandemic influenza with antiviral agents.
暂无分享,去创建一个
[1] J. Oxford,et al. Study of 1-adamantanamine hydrochloride used prophylactically during the Hong Kong influenza epidemic in the family environment. , 1969, Bulletin of the World Health Organization.
[3] E. D. Kilbourne,et al. The Influenza viruses and influenza , 1975 .
[4] W. Gerhard,et al. THE FUTURE IN VIRAL IMMUNOLOGY AND IMMUNOPATHOLOGY , 1975 .
[5] A. Langworthy,et al. An influenza simulation model for immunization studies. , 1976, American journal of epidemiology.
[6] I. Longini,et al. An optimization model for influenza A epidemics , 1978 .
[7] R. Couch,et al. Interpandemic influenza in the Houston area, 1974-76. , 1978, The New England journal of medicine.
[8] A. Monto,et al. Prevention of Russian influenza by amantadine. , 1979, JAMA.
[9] N. Grist. Pandemic influenza 1918. , 1979, British medical journal.
[10] L. A. Rvachev,et al. A mathematical model for the global spread of influenza , 1985 .
[11] I. Longini,et al. Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981. , 1985, American journal of epidemiology.
[12] I. Longini. The generalized discrete-time epidemic model with immunity: a synthesis , 1986 .
[13] I M Longini,et al. Predicting the global spread of new infectious agents. , 1986, American journal of epidemiology.
[14] E Ackerman,et al. Latin hypercube sampling and the sensitivity analysis of a Monte Carlo epidemic model. , 1988, International journal of bio-medical computing.
[15] I M Longini,et al. Statistical inference for infectious diseases. Risk-specific household and community transmission parameters. , 1988, American journal of epidemiology.
[16] O. Diekmann,et al. On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations , 1990, Journal of mathematical biology.
[17] I. Longini,et al. A generalized stochastic model for the analysis of infectious disease final size data. , 1991, Biometrics.
[18] A S Perelson,et al. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. , 1998, The Journal of infectious diseases.
[19] F. Hayden,et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. , 1998, The New England journal of medicine.
[20] M. Meltzer,et al. The economic impact of pandemic influenza in the United States: priorities for intervention. , 1999, Emerging infectious diseases.
[21] M. Halloran,et al. Design and interpretation of vaccine field studies. , 1999, Epidemiologic reviews.
[22] A. Monto,et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. , 1999, JAMA.
[23] A. Monto,et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. , 2000, The New England journal of medicine.
[24] Lihan K. Yan,et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. , 2000, The Journal of pediatrics.
[25] M E Halloran,et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. , 2000, Vaccine.
[26] Tom Britton. Epidemics in heterogeneous communities: estimation of "R" , 2001 .
[27] E. Garman,et al. The Origin and Control of Pandemic Influenza , 2001, Science.
[28] F. Hayden,et al. Perspectives on antiviral use during pandemic influenza. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[29] J. Oxford,et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. , 2001, JAMA.
[30] A. Nizam,et al. Containing Bioterrorist Smallpox , 2002, Science.
[31] A. Nizam,et al. Community interventions and the epidemic prevention potential. , 2002, Vaccine.
[32] Weber. Antimicrobial Therapy and Vaccines , 2002 .
[33] R. Webster,et al. Are We Ready for Pandemic Influenza? , 2003, Science.
[34] Keiji Fukuda,et al. Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.
[35] C. Fraser,et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong , 2003, The Lancet.
[36] I. Longini,et al. The critical vaccination fraction for heterogeneous epidemic models. , 2003, Mathematical biosciences.
[37] Susan Mallett,et al. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. , 2003, The Journal of antimicrobial chemotherapy.
[38] W. Casscells,et al. Influenza as a Bioweapon , 2003 .